Scientific Initiatives

Partnerships

Partnerships to Advance Science

The MRF has established important partnerships with leading research organizations. Specific partnerships include:

The Department of Defense (DoD)

The MRF strives to increase melanoma research funding through the Department of Defense. In addition to our lobbying efforts, the MRF recently created a 2018 DoD Research Funding Webinar, outlining the DoD Peer Reviewed Cancer Research Program (PRCRP) funding opportunities and application review process.

In 2018, the MRF led a coalition of advocates to successfully secure $10 million in dedicated research funding and the creation of the DoD Melanoma Research Program. Pre-proposals for the 2019 awards are due by 5:00pm ET on July 26, 2019 with formal applications accepted by invitation only. For those invited to submit a proposal, final applications will be due on October 23, 2019 by 11:59 ET. Additional information about the grants and who is eligible can be found here and pre-proposals can be submitted on the Congressionally Directed Medical Research Program (CDMRP) website.

The Society for Melanoma Research (SMR)

The MRF has partnered with SMR to sponsor two awards – a Young Investigator Award “presented to an individual researcher, in the junior stage (typically within first 5 years) of their career and who has made contributions in the area of melanoma research that significantly exceed the average for this career stage” and the Christopher J. Marshall Award “presented to a student who has made substantial published and original contributions to studies of signal transduction and melanoma within the previous two years”. In addition, since 2010, the MRF CURE OM Initiative has partnered with SMR to co-host its annual global science meeting.

The National Cancer Institute (NCI)

The MRF CURE OM Initiative co-hosted a global science meeting with the SMR and NCI which resulted in a publication as well as advocating for, and ultimately achieving, inclusion of ocular melanoma in The Cancer Genome Atlas (the results published in Cancer Cell).